| Dr Jason T Marko, DC | |
|
2041 Williston Rd, South Burlington, VT 05403-6078 | |
| (802) 863-0334 | |
| Not Available |
| Full Name | Dr Jason T Marko |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 7 Years |
| Location | 2041 Williston Rd, South Burlington, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659897155 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 006.0128429 (Vermont) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Drs. Marko Family Chiropractors | 9830273606 | 3 |
News Archive
Partnering with head and neck surgeons, pathologists at Dartmouth Hitchcock Medical Center's Norris Cotton Cancer Center developed a new use for an old test to determine if a patient's cancer is recurring, or if the biopsy shows benign inflammation of mucosal tissues. In Pathology - Research and Practice, lead author Candice C. Black, DO explained how her team confirmed the utility of ProExC, an existing antibody cocktail commonly used for pathology tests of the uterine cervix.
It seems an infarction, but it's not. It's called Tako-Tsubo syndrome, or stress-induced cardiomyopathy, and it's a rare disease which at first used to be confused with the far more common (and dangerous) cardiac infarction. Patients arrive to the emergency room with the characteristic heart attack symptoms: acute pain in the chest, an electrocardiogram with the typical changes and the release of those enzymes associated with the usual heart disease.
More than 330,000 total hip replacements are performed in the United States each year. Overall, it is a highly successful procedure. However, as with all surgeries, a risk for complications exists.
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
› Verified 4 days ago
| Provider Name | Drs. Marko Family Chiropractors |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1902923535 PECOS PAC ID: 9830273606 Enrollment ID: O20080304000033 |
News Archive
Partnering with head and neck surgeons, pathologists at Dartmouth Hitchcock Medical Center's Norris Cotton Cancer Center developed a new use for an old test to determine if a patient's cancer is recurring, or if the biopsy shows benign inflammation of mucosal tissues. In Pathology - Research and Practice, lead author Candice C. Black, DO explained how her team confirmed the utility of ProExC, an existing antibody cocktail commonly used for pathology tests of the uterine cervix.
It seems an infarction, but it's not. It's called Tako-Tsubo syndrome, or stress-induced cardiomyopathy, and it's a rare disease which at first used to be confused with the far more common (and dangerous) cardiac infarction. Patients arrive to the emergency room with the characteristic heart attack symptoms: acute pain in the chest, an electrocardiogram with the typical changes and the release of those enzymes associated with the usual heart disease.
More than 330,000 total hip replacements are performed in the United States each year. Overall, it is a highly successful procedure. However, as with all surgeries, a risk for complications exists.
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason T Marko, DC 2041 Williston Rd, South Burlington, VT 05403-6078 Ph: (802) 863-0334 | Dr Jason T Marko, DC 2041 Williston Rd, South Burlington, VT 05403-6078 Ph: (802) 863-0334 |
News Archive
Partnering with head and neck surgeons, pathologists at Dartmouth Hitchcock Medical Center's Norris Cotton Cancer Center developed a new use for an old test to determine if a patient's cancer is recurring, or if the biopsy shows benign inflammation of mucosal tissues. In Pathology - Research and Practice, lead author Candice C. Black, DO explained how her team confirmed the utility of ProExC, an existing antibody cocktail commonly used for pathology tests of the uterine cervix.
It seems an infarction, but it's not. It's called Tako-Tsubo syndrome, or stress-induced cardiomyopathy, and it's a rare disease which at first used to be confused with the far more common (and dangerous) cardiac infarction. Patients arrive to the emergency room with the characteristic heart attack symptoms: acute pain in the chest, an electrocardiogram with the typical changes and the release of those enzymes associated with the usual heart disease.
More than 330,000 total hip replacements are performed in the United States each year. Overall, it is a highly successful procedure. However, as with all surgeries, a risk for complications exists.
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
› Verified 4 days ago
Jennifer M Farrugia, ATC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 185 Tilley Dr, South Burlington, VT 05403 Phone: 802-879-1703 Fax: 802-863-9299 | |
Dr. Diana Adele Harkness, DC Chiropractor Medicare: Medicare Enrolled Practice Location: 4 Market St Ste 2, South Burlington, VT 05403 Phone: 802-497-2938 | |
Jenness Lee Kocsis, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 185 Tilley Dr, South Burlington, VT 05403 Phone: 802-879-1703 | |
Dr. Richard B Marko, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 2041 Williston Rd, South Burlington, VT 05403 Phone: 802-863-0334 Fax: 802-862-6604 | |
Dr. Dawn Ford, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 20 Kimball Ave, South Burlington, VT 05403 Phone: 802-343-3900 | |
Dr. John Glemb, Chiropractor Medicare: Medicare Enrolled Practice Location: 20 Joy Dr, Suite 100, South Burlington, VT 05403 Phone: 716-628-2936 | |
Dr. Paul M Samuel, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 595 Dorset St Ste 8, South Burlington, VT 05403 Phone: 802-557-8568 |